Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
- Promising data in the clinical trial with HDP-101 in multiple myeloma, including a complete remission in one patient; study progressing well
- First approvals for clinical trial with ATAC candidate HDP-102 received; study start soon
- Financial figures in line with plan with improved operating result and lower cash requirements
- Payment of USD 20 million from HealthCare Royalty significantly extends financing reach
- Conference call on March 2025 at 2:00 PM CET
Ladenburg, March 21, 2025 – Heidelberg Pharma AG (FWB: HPHA) today published its financial figures and annual report for the 2024 financial year (December 1, 2023 – November 30, 2024) as well as its outlook for 2025.
